While there is understandable excitement about the development of new cardiovascular drugs, an unmet and equally important need is to perform new clinical trials of old drugs, including to determine their longer-term effects and if and when they should be discontinued after years of use. New trials of old drugs can inform clinical practice and are much needed.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Tricoci, P., Allen, J. M., Kramer, J. M., Califf, R. M. & Smith, S. C. Jr Scientific evidence underlying the ACC/AHA clinical practice guidelines. J. Am. Med. Assoc. 301, 831–841 (2009).
Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709–717 (1999).
Nidorf, S. M. et al. Colchicine in patients with chronic coronary disease. N. Engl. J. Med. 383, 1838–1847 (2020).
Cuffe, M. S. et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. J. Am. Med. Assoc. 287, 1541–1547 (2002).
Mathew, R. et al. Milrinone as compared with dobutamine in the treatment of cardiogenic shock. N. Engl. J. Med. 385, 516–525 (2021).
HPS2-THRIVE Collaborative Group et al. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med. 371, 203–212 (2014).
Boardman, H. M. P. et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst. Rev. 3, CD002229 (2015).
Chen, Z. M. et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366, 1622–1632 (2005).
Jong, P., Yusuf, S., Rousseau, M. F., Ahn, S. A. & Bangdiwala, S. I. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 361, 1843–1848 (2003).
Jaeger, B. C. et al. Longer-term all-cause and cardiovascular mortality with intensive blood pressure control: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 7, 1138–1146 (2022).
C.B.G. has received consulting fees from AbbVie, Abiomed, Alnylam Pharmaceuticals, Anthos, Bayer Corporation, Boehringer Ingelheim, Boston Scientific Corporation, Bristol Myers Squibb, Cardionomics, CeleCor Therapeutics, Janssen Pharmaceutical, Medtronic, Merck, Novo Nordisk, Novartis Pharmaceutical Company, PLX Pharma, Pfizer and Philips. C.B.G. also has salary funded by Duke University grants sponsored by Boehringer Ingelheim, the Food and Drug Administration, Novartis Pharmaceutical Company and Philips. C.B.G. has equity in Tenac.io. The other authors declare no competing interests.
About this article
Cite this article
Granger, C.B., Pocock, S.J. & Gersh, B.J. The need for new clinical trials of old cardiovascular drugs. Nat Rev Cardiol 20, 71–72 (2023). https://doi.org/10.1038/s41569-022-00819-1